Short answer
The best evidence for psilocybin and anxiety comes from people with life-threatening cancer, where two randomized trials found a single session produced large, lasting reductions in anxiety and depression. Real-world data from Oregon's licensed program also shows big drops in anxiety three months after a session. Psilocybin isn't approved for any anxiety disorder, and it can cause anxiety in the short term.
Key takeaways
- Two 2016 randomized trials found one psilocybin session cut anxiety and depression in people with life-threatening cancer, with benefits lasting months.
- In Oregon's licensed program, the risk of significant anxiety three months after a session was about 70% lower than at baseline.
- No large trial has tested psilocybin specifically for generalized anxiety disorder yet.
- Anxiety during the session is common, which is why preparation and support matter.
The cancer trials
The modern era of psilocybin research basically started with anxiety. A 2011 UCLA pilot gave a modest dose to 12 people with advanced cancer and found it was safe and reduced anxiety over the following months.5 Then, in 2016, two larger randomized trials published side by side:
- Johns Hopkins gave 51 cancer patients a high dose and a very low comparison dose in different sessions. The high dose produced large decreases in anxiety and depression, and about 80% still showed clinically meaningful improvement six months later.1
- NYU compared psilocybin with niacin in 29 patients and found rapid, sustained reductions in anxiety and depression, along with less hopelessness and existential distress.2
Both studies also found improvements in quality of life, sense of meaning, and attitudes toward death. For people facing a terminal diagnosis, that last part matters a lot.
Real-world results from Oregon
Oregon's licensed program gives us a look at psilocybin outside a clinical trial. A 2026 study in JAMA Network Open followed 346 clients from 24 service centers. Three months after their session, their risk of significant anxiety symptoms was about 70% lower than before.3 There was no placebo group, and clients chose to go, so expectation likely played a role. Still, it's a large drop in a real-world population.
Why a drug that can cause anxiety might treat it
Anxiety often runs on loops: the same worried thoughts replaying, the same threats rehearsed. Brain imaging suggests psilocybin temporarily disrupts the default mode network, the system most involved in that kind of self-focused thinking.4 People often describe stepping outside their usual worries and seeing them from a distance. The leading theory is that, with good support, that perspective can stick.
The catch is that facing difficult emotions during a session can be uncomfortable in the moment. The trials above handled that with preparation sessions, a calm room, and trained monitors present throughout. Read more in what helps during a difficult experience.
What we don't know yet
Psilocybin hasn't been tested in a large trial for generalized anxiety disorder, panic disorder, or social anxiety specifically. The strongest results come from anxiety connected to serious illness, which may respond differently from everyday anxiety disorders. Watch for trial results, and if you're interested, check ClinicalTrials.gov.
Common questions
Can psilocybin help with social anxiety?
It hasn't been well studied for social anxiety specifically. Related research is exploring other psychedelic compounds for social anxiety, including an MDMA-like drug now owned by Eli Lilly, but psilocybin data is limited.
Will psilocybin make my anxiety worse?
It can during the experience. Many people feel some anxiety at some point during a session. Outcomes are better with preparation, a calm setting, and a trained person present. People with severe anxiety should talk with a clinician first.
How is this different from taking a benzodiazepine?
Benzodiazepines quiet anxiety while they're in your system and can cause dependence. Psilocybin is given rarely, and the goal is a lasting change in how a person relates to their fears, not short-term sedation.
Sources
- Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology. 2016. doi.org/10.1177/0269881116675513
- Ross S, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. Journal of Psychopharmacology. 2016. doi.org/10.1177/0269881116675512
- Korthuis PT, et al. Safety and mental health outcomes of Oregon state-regulated psilocybin services. JAMA Network Open. 2026. doi.org/10.1001/jamanetworkopen.2026.30608
- Carhart-Harris RL, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS. 2012. doi.org/10.1073/pnas.1119598109
- Grob CS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry. 2011. doi.org/10.1001/archgenpsychiatry.2010.116
This article is for education only and is not medical or legal advice. Psilocybin is a Schedule I substance under U.S. federal law. Talk with a licensed clinician before making decisions about your health. In a crisis, call or text 988.